Results 31 to 40 of about 10,096 (205)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification. [PDF]

Medicine (Baltimore), 2020
Neuroblastoma (NB) with MYCN amplification has a poor prognosis and high mortality. The potential molecular biological relationship between clinical features and MYCN amplification should be explored.NB patients were examined by fluorescence in situ hybridization (FISH) for MYCN amplification in the tumor mass or bone marrow samples to determine ...
Huang C, Jiang S, Yang J, Liao X, Li Y, Li S.   +5 more
europepmc   +3 more sources

Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification [PDF]

Proceedings of the National Academy of Sciences, 2004
The mechanisms causing persistence of embryonal cells that later give rise to tumors is unknown. One tumorigenic factor in the embryonal childhood tumor neuroblastoma is the MYCN protooncogene. Here we show that normal mice developed neuroblast hyperplasia in paravertebral ganglia at birth that completely regressed ...
Loen M. Hansford, Wayne Thomas, Joanna Keating, Catherine A. Burkhart, Anne E. Peaston, Murray D. Norris, Michelle Haber, Patricia J. Armati, William A. Weiss, Glenn M. Marshall   +9 more
openalex   +3 more sources

MYCN gene amplification in rhabdomyosarcoma [PDF]

Cancer, 1994
Amplification of the MYCN oncogene, formerly known as N-myc, has been seen in several malignant tumors, particularly neuroblastoma, where its association with a poor clinical outcome is the clearest example of a clinically relevant oncogene mutation in any human cancer.The incidence and clinical significance of MYCN amplification in rhabdomyosarcoma ...
D, Driman, P S, Thorner, M L, Greenberg, S, Chilton-MacNeill, J, Squire   +4 more
openaire   +2 more sources

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets

BMC Pediatrics, 2020
Background Neuroblastoma patients with MYCN amplification are associated with poor prognosis. However, the prognostic relevance of MYCN associated genes in neuroblastoma is unclear. Methods The expression profiles of MYCN associated genes were identified
Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao   +4 more
doaj   +1 more source

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma

Cancers, 2023
Cancer is a disease caused by (epi)genomic and gene expression abnormalities and characterized by metabolic phenotypes that are substantially different from the normal phenotypes of the tissues of origin. Metabolic reprogramming is one of the key features of tumors, including those established in the human nervous system.
Marialena Pouliou, Marianna A. Koutsi, Lydia Champezou, Angeliki-Ioanna Giannopoulou, Giannis Vatsellas, Christina Piperi, Marios Agelopoulos   +6 more
openaire   +3 more sources

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification [PDF]

Proceedings of the National Academy of Sciences, 2012
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor prognosis.
Valentijn, Linda J., Koster, Jan, Haneveld, Franciska, Aissa, Rachida Ait, van Sluis, Peter, Broekmans, Marloes E. C., Molenaar, Jan J., van Nes, Johan, Versteeg, Rogier   +8 more
openaire   +3 more sources

MYCN in Neuroblastoma: “Old Wine into New Wineskins”

Diseases, 2021
MYCN Proto-Oncogene, BHLH Transcription Factor (MYCN) has been one of the most studied genes in neuroblastoma. It is known for its oncogenetic mechanisms, as well as its role in the prognosis of the disease and it is considered one of the prominent ...
Maria Braoudaki, Kyriaki Hatziagapiou, Apostolos Zaravinos, George I. Lambrou   +3 more
doaj   +1 more source

Copy Number Analysis Reveal Genetic Risks of Penile Cancer

Frontiers in Oncology, 2020
ObjectivesTo evaluate copy number alterations (CNAs) in genes associated with penile cancer (PeC) and determine their correlation and prognostic ability with PeC.MethodsWhole-exome sequencing was performed for tumor tissue and matched normal DNA of 35 ...
Yongbo Yu, Chengwen Gao, Chengwen Gao, Yuanbin Chen, Meilan Wang, Jianfeng Zhang, Xiaocheng Ma, Shuaihong Liu, Hang Yuan, Zhiqiang Li, Zhiqiang Li, Haitao Niu   +11 more
doaj   +1 more source

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma

Clinical and Translational Medicine, 2023
AbstractBackgroundMYCN amplification as a common genetic alteration that correlates with a poor prognosis for neuroblastoma (NB) patients. However, given the challenge of directly targeting MYCN, indirect strategies to modulate MYCN by interfering with its cofactors are attractive in NB treatment. Although cyclin B1 interacting protein 1 (CCNB1IP1) has
Yang Zhou, Hui Yan, Qiang Zhou, Penggao Wang, Fang Yang, Ziqiao Yuan, Qianming Du, Bo Zhai   +7 more
openaire   +3 more sources